These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17228474)

  • 41. Initial antiretroviral drugs.
    Rojo P; Gonzalez-Tome MI; Ramos JT
    Pediatr Infect Dis J; 2007 Dec; 26(12):1167; author reply 1167. PubMed ID: 18043466
    [No Abstract]   [Full Text] [Related]  

  • 42. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 43. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 44. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update from CROI 2008 on HIV-related infections and conditions.
    McCord A
    Proj Inf Perspect; 2008 Apr; (45):17-24. PubMed ID: 19248294
    [No Abstract]   [Full Text] [Related]  

  • 46. Similar challenges with retention in care issues.
    Krentz HB; Siemieniuk RA; Gill MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527. PubMed ID: 17990241
    [No Abstract]   [Full Text] [Related]  

  • 47. Predicting the potential benefits of early initiation of ART: time to do a trial to find out.
    Phillips AN; Emery S
    Curr Opin HIV AIDS; 2009 May; 4(3):165-6. PubMed ID: 19532044
    [No Abstract]   [Full Text] [Related]  

  • 48. Side effects. Using metabolomics for predicting side effects.
    TreatmentUpdate; 2005; 17(5):11-2. PubMed ID: 17219662
    [No Abstract]   [Full Text] [Related]  

  • 49. Full viral suppression newest trend seen in the "post-HAART" era. New immunotherapy treatment could help with trend.
    AIDS Alert; 2008 Mar; 23(3):25-7. PubMed ID: 18661635
    [No Abstract]   [Full Text] [Related]  

  • 50. Early initiation of ART produces better clinical outcomes.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301458
    [No Abstract]   [Full Text] [Related]  

  • 51. [New therapies in the management of seropositive persons].
    Riou JM
    Soins; 2009 Apr; (734):54. PubMed ID: 19475834
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years.
    Briz V; Poveda E; López M; González Mdel M; Soriano V; Benito JM
    AIDS; 2008 Jul; 22(11):1371-4. PubMed ID: 18580618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. State publishes acute infection guidelines.
    AIDS Patient Care STDS; 2003 Jan; 17(1):43. PubMed ID: 12622117
    [No Abstract]   [Full Text] [Related]  

  • 54. HAART at 10: an interview with Joseph Gathe.
    Gathe J
    Res Initiat Treat Action; 2005; 11(1):46-8. PubMed ID: 16208820
    [No Abstract]   [Full Text] [Related]  

  • 55. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 56. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
    Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
    Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 58. Maturation inhibitors as new antiretroviral agents.
    Richards J; McCallister S
    J HIV Ther; 2008 Dec; 13(4):79-82. PubMed ID: 19418657
    [No Abstract]   [Full Text] [Related]  

  • 59. Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Szczech LA
    Curr Opin HIV AIDS; 2009 May; 4(3):167-70. PubMed ID: 19532045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Travel medicine and HIV infection.
    Igreja R
    Int J STD AIDS; 2008 Sep; 19(9):577-80. PubMed ID: 18725545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.